Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Nike Founder Phil Knight Gives Away a Billion Dollars – the Largest Single Donation to a Public University
United Kingdom
-
ADHD and autism appear more common among young people diagnosed with type 2 diabetes
United Kingdom
-
Kidney disease, heart failure or death risk climbs to 55% 10 years after type 2 diabetes diagnosis
United Kingdom
-
Reducing ultra-processed foods, being physically active can cut risk of type 2 diabetes, regardless of genetic makeup
United Kingdom
-
Blood test shows whether newborns with fever have bacterial or viral infection
United Kingdom
-
Leg pain can warn of a serious condition: Why peripheral artery disease (PAD) needs more attention
United Kingdom
-
Nonprofit Puts Ex-Cons to Work with Paid Apprenticeships as Machinists in California
United Kingdom
-
The brain still responds to favorite music in dementia
United Kingdom